[go: up one dir, main page]

RU2005105301A - Парентеральные композиции, содержащие гидроксиэфиры рапамицина - Google Patents

Парентеральные композиции, содержащие гидроксиэфиры рапамицина Download PDF

Info

Publication number
RU2005105301A
RU2005105301A RU2005105301/15A RU2005105301A RU2005105301A RU 2005105301 A RU2005105301 A RU 2005105301A RU 2005105301/15 A RU2005105301/15 A RU 2005105301/15A RU 2005105301 A RU2005105301 A RU 2005105301A RU 2005105301 A RU2005105301 A RU 2005105301A
Authority
RU
Russia
Prior art keywords
solvent
polyethylene glycol
cci
composition
polysorbate
Prior art date
Application number
RU2005105301/15A
Other languages
English (en)
Other versions
RU2344821C2 (ru
Inventor
Джозеф Т. РУБИНО (US)
Джозеф Т. Рубино
Виктори СИСКАВИЧ (US)
Виктория Сискавич
Морин М. ХАРРИСОН (US)
Морин М. Харрисон
Пойа ГАНДИ (US)
Пойа Ганди
Original Assignee
Уайт (Us)
Уайт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188593&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2005105301(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Уайт (Us), Уайт filed Critical Уайт (Us)
Publication of RU2005105301A publication Critical patent/RU2005105301A/ru
Application granted granted Critical
Publication of RU2344821C2 publication Critical patent/RU2344821C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (30)

1. Концентрат сорастворителя и CCI-779, который включает CCI-779, растворитель, приемлемый для парентерального применения, и антиоксидантный компонент.
2. Концентрат сорастворителя по п. 1, где растворителем, приемлемым для парентерального применения, является диметилацетамид.
3. Концентрат сорастворителя по п. 1, где растворителем, приемлемым для парентерального применения, является спиртовой растворитель.
4. Концентрат сорастворителя по п. 3, где спиртовой растворитель включает этанол, пропиленгликоль, полиэтиленгликоль 300, полиэтиленгликоль 400, полиэтиленгликоль 600 или полиэтиленгликоль 1000.
5. Концентрат сорастворителя по любому из пп. 1-4, где антиоксидантный компонент включает лимонную кислоту, глицин, d,1--токоферол, BHA, BHT, монотиоглицерин, аскорбиновую кислоту или пропилгаллат.
6. Концентрат сорастворителя и CCI-779 по п.1, который включает CCI-779, лимонную кислоту и дегидратированный этанол.
7. Концентрат сорастворителя и CCI-779 по п.1, который включает CCI-779, дегидратированный этанол, d,1-α-токоферол и пропиленгликоль.
8. Концентрат сорастворителя по п. 7, который дополнительно включает лимонную кислоту.
9. Концентрат сорастворителя по п.1, где CCI-779 составляет от около 0,05 мг/мл до около 50 мг/мл.
10. Концентрат сорастворителя по п.1, где CCI-779 составляет от около 25 мг/мл.
11. Концентрат сорастворителя по п.1, где антиоксидант составляет от около 0,001% до 1,0% мас./об.
12. Парентеральная композиция, которая включает CCI-779, спиртовой растворитель, антиоксидант, разбавляющий растворитель и поверхностно-активное вещество.
13. Композиция по п.12, где спиртовым растворителем является этанол, пропиленгликоль, полиэтиленгликоль 300, полиэтиленгликоль 400, полиэтиленгликоль 600 или полиэтиленгликоль 1000.
14. Композиция по п.12 или 13, где антиоксидантом является лимонная кислота, глицин, d,1-α-токоферол, BHA, BHT, монотиоглицерин, аскорбиновая кислота или пропилгаллат.
15. Композиция по п.12, где разбавляющим растворителем является вода, этанол, полиэтиленгликоль 300, полиэтиленгликоль 400, полиэтиленгликоль 600, полиэтиленгликоль 1000 или пропиленгликоль.
16. Композиция по по п.12, где поверхностно-активным веществом является полисорбат 20, полисорбат 80, желчная кислота, лецитин, этоксилированное растительное масло, пропиленгликольсукцинат токоферола витамина Е или блоксополимеры полиоксиэтилена-полиоксипропилена.
17. Композиция по по п.12, где CCI-779 составляет от около 1 мг/мл до около 25 мг/мл.
18. Композиция по по п.12, где CCI-779 составляет от около 2,5 мг/мл до около 10 мг/мл.
19. Композиция по п.12, где антиоксидант составляет от около 0,0005% мас./об. до около 0,5% мас./об. композиции.
20. Композиция по п.12, где поверхностно-активное вещество составляет от около 0,5% мас./об. до около 10% мас./об. композиции.
21. Композиция по по п.12, где растворитель составляет от около 10% мас./об. до около 90% мас./об. композиции.
22. Способ получения парентеральной композиции CCI-779, который включает:
(а) смешивание CCI-779 с растворителем, приемлемым для парентерального применения, и антиоксидантным компонентом для получения концентрата сорастворителя;
(b) смешивание разбавляющего раствора и поверхностно-активного вещества для получения разбавителя; и
(с) смешивание концентрата сорастворителя с разбавителем для получения парентеральной композиции CCI-779.
23. Способ по п.22, где растворителем является спиртовой растворитель, включающий этанол, пропиленгликоль, полиэтиленгликоль 300, полиэтиленгликоль 400, полиэтиленгликоль 600 или полиэтиленгликоль 1000.
24. Способ по п.22 или 23, где антиоксидантный компонент включает лимонную кислоту, d,1-α-токоферол, BHA, BHT, монотиоглицерин, аскорбиновую кислоту или пропилгаллат.
25. Способ по п.22, где разбавляющим растворителем является вода, этанол, полиэтиленгликоль 300, полиэтиленгликоль 400, полиэтиленгликоль 600, полиэтиленгликоль 1000 или пропиленгликоль.
26. Способ по п.22, где поверхностно-активным веществом является полисорбат 20, полисорбат 80, желчная кислота, лецитин, этоксилированное растительное масло, пропиленгликольсукцинат токоферола витамина Е или блок-сополимеры полиоксиэтилена-полиоксипропилена.
27. Способ по п.22, где растворителем является дегидратированный этанол, антиоксидантом является лимонная кислота, разбавляющими растворителями являются вода и полиэтиленгликоль 400 и поверхностно-активным веществом является полисорбат 20 или полисорбат 80.
28. Способ по п.22, где растворителем является дегидратированный этанол, антиоксидантом является лимонная кислота, разбавляющими растворителями являются дегидратированный этанол и полиэтиленгликоль 400 и поверхностно-активным веществом является полисорбат 20 или полисорбат 80.
29. Способ по п.22, где растворителями являются дегидратированный этанол и пропиленгликоль, антиоксидантом является d,1-α-токоферол, разбавляющими растворителями являются вода и полиэтиленгликоль 400 и поверхностно-активным веществом является полисорбат 20 или полисорбат 80.
30. Способ по п.22, где растворителями являются дегидратированный этанол и пропиленгликоль, антиоксидантом является d,1-α-токоферол, разбавляющими растворителями являются дегидратированный этанол и полиэтиленгликоль 400, и поверхностно-активным веществом является полисорбат 20 или полисорбат 80.
RU2005105301/15A 2002-07-30 2003-07-25 Парентеральные композиции, содержащие гидроксиэфиры рапамицина RU2344821C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39952602P 2002-07-30 2002-07-30
US60/399,526 2002-07-30

Publications (2)

Publication Number Publication Date
RU2005105301A true RU2005105301A (ru) 2005-09-10
RU2344821C2 RU2344821C2 (ru) 2009-01-27

Family

ID=31188593

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005105301/15A RU2344821C2 (ru) 2002-07-30 2003-07-25 Парентеральные композиции, содержащие гидроксиэфиры рапамицина

Country Status (27)

Country Link
US (4) US8026276B2 (ru)
EP (1) EP1553940B1 (ru)
JP (2) JP2005537285A (ru)
KR (1) KR101131794B1 (ru)
CN (1) CN100402031C (ru)
AR (2) AR040693A1 (ru)
AT (1) ATE385795T1 (ru)
AU (2) AU2003254168A1 (ru)
BR (1) BR0313024A (ru)
CA (1) CA2493878C (ru)
CO (1) CO5700745A2 (ru)
CR (1) CR7647A (ru)
DE (1) DE60319118T2 (ru)
DK (1) DK1553940T3 (ru)
EC (1) ECSP055628A (ru)
ES (1) ES2300622T3 (ru)
IL (1) IL166003A (ru)
MX (1) MXPA05001013A (ru)
NO (1) NO20050455L (ru)
NZ (1) NZ537829A (ru)
PT (1) PT1553940E (ru)
RU (1) RU2344821C2 (ru)
SI (1) SI1553940T1 (ru)
TW (1) TWI307277B (ru)
UA (1) UA82328C2 (ru)
WO (1) WO2004011000A1 (ru)
ZA (1) ZA200500831B (ru)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI307277B (en) 2002-07-30 2009-03-11 Wyeth Corp Parenteral formulations
MXPA05002828A (es) * 2002-09-17 2005-05-27 Wyeth Corp Formulaciones orales.
ES2494791T3 (es) * 2002-09-18 2014-09-16 Trustees Of The University Of Pennsylvania Uso de rapamicina para el tratamiento o prevención de la degeneración macular asociada a la edad
CA2532251A1 (en) * 2003-07-25 2005-02-10 Wyeth Cci-779 lyophilized formulations
CN1882338A (zh) 2003-09-18 2006-12-20 马库赛特公司 经巩膜递送
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
EP1737869A1 (en) 2004-04-14 2007-01-03 Wyeth a Corporation of the State of Delaware Regiospecific synthesis of rapamycin 42-ester derivatives
AU2005233612A1 (en) 2004-04-14 2005-10-27 Wyeth Proline CCI-779 (proline-rapamycin 42-ester with 2,2-bis (hydroxymethyl) propionic acid) and two-step enzymatic synthesis of proline CCI-779 and CCI-779 using microbial lipase
AU2005238493A1 (en) * 2004-04-27 2005-11-10 Wyeth Labeling of rapamycin using rapamycin-specific methylases
KR20070070184A (ko) * 2004-10-28 2007-07-03 와이어쓰 자궁근종의 치료에 있어서 ｍＴＯＲ 억제제의 용도
HUE027352T2 (en) 2005-02-09 2016-09-28 Santen Pharmaceutical Co Ltd Liquid formulations for the treatment of diseases or conditions
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
CA2596392A1 (en) * 2005-02-15 2006-08-24 Wyeth Orally bioavailable cci-779 tablet formulations
WO2007056175A2 (en) * 2005-11-04 2007-05-18 Wyeth 41-methoxy isotope labeled rapamycin 42-ester
WO2007056118A1 (en) 2005-11-04 2007-05-18 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
WO2007075621A1 (en) * 2005-12-20 2007-07-05 Wyeth Control of cci-779 dosage form stability through control of drug substance impurities
BRPI0707612B8 (pt) * 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
AU2013200089B2 (en) * 2006-02-09 2016-03-03 Santen Pharmaceutical Co., Ltd Stable formulations, and methods of their preparation and use
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
TW200901989A (en) 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
WO2009120933A2 (en) 2008-03-28 2009-10-01 Particle Sciences, Inc. Pharmaceutical solutions and method for solubilizing therapeutic agents
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
WO2011094565A1 (en) 2010-01-28 2011-08-04 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
WO2011151704A2 (en) * 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
US20120252835A1 (en) * 2011-04-01 2012-10-04 Astron Research Limited Stable temsirolimus composition and process of preparing same
EP2717884A1 (en) 2011-06-06 2014-04-16 Chevron Phillips Chemical Company LP Use of metallocene compounds for cancer treatment
JP6250628B2 (ja) 2012-03-20 2017-12-20 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチンの製剤
PL3533447T3 (pl) 2012-03-20 2023-07-17 Eagle Pharmaceuticals, Inc. Ciekłe kompozycje bendamustyny do zastosowania w sposobie leczenia stanów reagujących na bendamustynę u pacjentów wymagających obniżonych objętości do podawania
WO2014118696A2 (en) * 2013-01-29 2014-08-07 Gland Pharma Limited Pharmacuetical compositions of rapamycin esters and its derivatives
CN103989676B (zh) * 2014-06-10 2016-06-22 福建省微生物研究所 可注射用的替西罗莫司组合物
EP3351245A4 (en) * 2015-09-18 2019-05-22 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF
US10765665B2 (en) 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
CN105640878A (zh) * 2016-01-25 2016-06-08 宿州学院 一种坦西莫司注射用浓溶液及其制备方法
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
CN105687132B (zh) * 2016-03-17 2020-06-12 鲁南贝特制药有限公司 一种坦西莫司注射用浓溶液及其制备方法
CN107550852B (zh) * 2016-06-30 2021-05-14 山东新时代药业有限公司 一种坦西莫司注射液注射用溶剂及其制备方法
CN107773539A (zh) * 2016-08-27 2018-03-09 鲁南制药集团股份有限公司 一种注射用坦西莫司及其制备方法
WO2018057788A1 (en) * 2016-09-22 2018-03-29 Mercator Medsystems, Inc. Treatment of restenosis using temsirolimus
EP3629774A4 (en) 2017-05-26 2021-03-03 Mercator Medsystems, Inc. COMBINATION THERAPY FOR TREATMENT OF RESTENOSIS
WO2019162048A1 (en) 2018-02-23 2019-08-29 Biotronik Ag Parenteral formulation materials and methods for 40-o-cyclic hydrocarbon esters and related structures
WO2019178228A1 (en) 2018-03-14 2019-09-19 Mercator Medsystems, Inc. Medical instrument and medical method for localized drug delivery
JP7608195B2 (ja) * 2020-02-14 2025-01-06 エボニック オペレーションズ ゲーエムベーハー ２，４，７，９－テトラメチル－５－デシン－４，７－ジオール系無溶媒組成物
EP4259100A1 (en) * 2020-12-14 2023-10-18 Biotronik Ag Materials and methods for treating viral and other medicinal conditions
CN114366715A (zh) * 2022-01-28 2022-04-19 严鹏科 雷帕霉素自微乳注射剂及其制备方法及其应用

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4401653A (en) 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5023264A (en) 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
GB9103430D0 (en) 1991-02-19 1991-04-03 Smithkline Beecham Plc Novel compound
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
ATE135583T1 (de) 1991-06-18 1996-04-15 American Home Prod Verwendung von rapamycin zur behandlung von t- zellen lymphom/leukämie bei erwachsenen
ZA924953B (en) 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
ATE193652T1 (de) 1992-03-30 2000-06-15 American Home Prod Rapamycin formulierung zur iv-injektion
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
IL111008A (en) * 1993-09-30 1999-10-28 American Home Prod Rapamycin formulations for intravenous injection and their preparation
US5536729A (en) 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5616588A (en) 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
IL111003A0 (en) 1993-09-30 1994-11-28 American Home Prod Multi-component oral rapamycin formulation
US5516770A (en) * 1993-09-30 1996-05-14 American Home Products Corporation Rapamycin formulation for IV injection
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US6022852A (en) 1993-10-22 2000-02-08 Hexal Ag Pharmaceutical composition containing cyclosporin A
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5447936A (en) 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
GB2327611B (en) 1994-10-26 1999-06-02 Novartis Ag Macrolide compositions
IL115742A (en) 1994-10-26 2000-06-01 Novartis Ag Pharmaceutical compositions comprising a difficultly soluble active agent a hydrophilic phase a lipophilic phase and a surfactant
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
NZ280689A (en) 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
IL131217A0 (en) 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
WO1999056727A2 (en) 1998-05-07 1999-11-11 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
GB9826882D0 (en) 1998-12-07 1999-01-27 Novartis Ag Organic compounds
WO2001008678A1 (en) * 1999-07-30 2001-02-08 University Of Kentucky Research Foundation Cis-2,6-disubstituted piperidines for the treatment of psychostimulant abuse and withdrawal, eating disorders, and central nervous system diseases and pathologies
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
ES2283344T3 (es) 1999-10-29 2007-11-01 Kosan Biosciences, Inc. Analogos de la rapamicina.
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
US20020013335A1 (en) * 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
JP2004509898A (ja) * 2000-09-19 2004-04-02 ワイス 水溶性ラパマイシンエステル
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
EP1407013B1 (en) 2001-07-18 2007-09-12 Bionomics Limited Mutations in ion channels
BR0211905A (pt) 2001-08-22 2004-09-21 Wyeth Corp Dialdeìdos de rapamicina
BR0211986A (pt) 2001-08-22 2004-09-28 Wyeth Corp 29-enóis de rapamicina
US20030176455A1 (en) 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
TWI307277B (en) 2002-07-30 2009-03-11 Wyeth Corp Parenteral formulations
ATE483822T1 (de) * 2002-10-11 2010-10-15 Univ Erasmus Primer für nukleinsäureamplifikation in pcr- basierten klonalitätsstudien
AU2004259669A1 (en) 2003-07-16 2005-02-03 Wyeth CCI-779 Isomer C
CA2532251A1 (en) 2003-07-25 2005-02-10 Wyeth Cci-779 lyophilized formulations
JP4227649B2 (ja) 2003-08-07 2009-02-18 ワイス Ｃｃｉ−７７９の位置選択的合成
AU2005238432A1 (en) 2004-04-14 2005-11-10 Wyeth Process for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
AU2005233612A1 (en) 2004-04-14 2005-10-27 Wyeth Proline CCI-779 (proline-rapamycin 42-ester with 2,2-bis (hydroxymethyl) propionic acid) and two-step enzymatic synthesis of proline CCI-779 and CCI-779 using microbial lipase
EP1737869A1 (en) 2004-04-14 2007-01-03 Wyeth a Corporation of the State of Delaware Regiospecific synthesis of rapamycin 42-ester derivatives
PE20060642A1 (es) 2004-08-10 2006-08-01 Wyeth Corp Derivados de 42-ester de rapamicina con acido 2,2-bis(hidoximetil)propionico (cci-779) y metodos para su preparacion
AR050374A1 (es) 2004-08-20 2006-10-18 Wyeth Corp Forma polimorfica de rafampicina
MX2007007409A (es) 2004-12-20 2007-07-12 Wyeth Corp Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos.
HN2005035605A (es) 2004-12-20 2010-08-05 Wyeth Corp Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios
CA2596392A1 (en) 2005-02-15 2006-08-24 Wyeth Orally bioavailable cci-779 tablet formulations
MX2007010716A (es) 2005-03-02 2008-01-16 Wyeth Corp Purificacion de rapamicina.
US7622578B2 (en) 2005-12-07 2009-11-24 Wyeth Scalable process for the preparation of a rapamycin 42-ester from a rapamycin 42-ester boronate
WO2007075621A1 (en) 2005-12-20 2007-07-05 Wyeth Control of cci-779 dosage form stability through control of drug substance impurities

Also Published As

Publication number Publication date
US8299116B2 (en) 2012-10-30
BR0313024A (pt) 2005-07-12
KR20050026025A (ko) 2005-03-14
SI1553940T1 (sl) 2008-08-31
HK1076390A1 (en) 2006-01-20
TW200403073A (en) 2004-03-01
AU2010200761A1 (en) 2010-03-18
MXPA05001013A (es) 2005-05-16
ES2300622T3 (es) 2008-06-16
EP1553940B1 (en) 2008-02-13
US8026276B2 (en) 2011-09-27
CA2493878A1 (en) 2004-02-05
JP2005537285A (ja) 2005-12-08
AR040693A1 (es) 2005-04-13
ATE385795T1 (de) 2008-03-15
CN1671385A (zh) 2005-09-21
UA82328C2 (ru) 2008-04-10
ECSP055628A (es) 2005-05-30
AU2003254168A1 (en) 2004-02-16
PT1553940E (pt) 2008-05-09
US20130252998A1 (en) 2013-09-26
US8722700B2 (en) 2014-05-13
WO2004011000A1 (en) 2004-02-05
IL166003A (en) 2009-05-04
NZ537829A (en) 2006-09-29
US20040167152A1 (en) 2004-08-26
US20130040980A1 (en) 2013-02-14
RU2344821C2 (ru) 2009-01-27
CO5700745A2 (es) 2006-11-30
KR101131794B1 (ko) 2012-03-30
DE60319118T2 (de) 2009-02-05
CA2493878C (en) 2013-07-23
US20110294845A1 (en) 2011-12-01
NO20050455L (no) 2005-02-09
CN100402031C (zh) 2008-07-16
JP5345105B2 (ja) 2013-11-20
AU2010200761B2 (en) 2011-10-13
US8455539B2 (en) 2013-06-04
IL166003A0 (en) 2006-01-15
DK1553940T3 (da) 2008-06-02
TWI307277B (en) 2009-03-11
CR7647A (es) 2006-05-26
DE60319118D1 (de) 2008-03-27
JP2010163466A (ja) 2010-07-29
EP1553940A1 (en) 2005-07-20
AR090603A2 (es) 2014-11-26
ZA200500831B (en) 2007-07-25

Similar Documents

Publication Publication Date Title
RU2005105301A (ru) Парентеральные композиции, содержащие гидроксиэфиры рапамицина
AU2004228041B2 (en) Topical anthelmintic veterinary formulations
CY1120513T1 (el) Υψηλης συμπυκνωσης συνθεση μινοξιδιλης
BR0210505A (pt) Formulações auto-emulsionantes de inibidores da proteìna de transferência de ésteres de colesterilo
RU2013100984A (ru) Офтальмологические композиции для введения активных жирорастворимых ингредиентов
EP1273299B1 (en) Minoxidil-containing preparations
CO5700671A2 (es) Formulaciones topicas que comprenden un derivado de 1-n-arilpirazol y una formamidina
KR960016904A (ko) 사이클로스포린-함유 연질캅셀제 조성물
RU2005110414A (ru) Использование поверхностно-активных веществ для солюбилизации нерастворимых в воде твердых веществ в напитках
KR870009720A (ko) 서방형 신규 제약 제제물
TW200601971A (en) Stable and water-soluble plant growth regulator liquid compositions and methods for use of same
CA2273327A1 (en) Stabilized ascorbyl compositions
RU2006136805A (ru) Крем-гель, содержащий ивермектин
EA200400646A1 (ru) Способ и композиция для улучшения сгорания топлива
KR970064620A (ko) 사이클로스포린-함유 외용약제 조성물
US20070243101A1 (en) Cleaning composition with agricultural crop solvent and hydrogen peroxide
PE20071067A1 (es) Composiciones de rapamicina y cci-779 y metodo para su preparacion
RU2013126259A (ru) Фармацевтическая композиция таксоидов
KR20000035978A (ko) 아버멕틴 및 밀베마이신의 주사가능한 제제
ES2572133T3 (es) Composiciones farmacéuticas que comprenden un derivado de camptotecina
AU2007202548B1 (en) Pesticide Composition
NO20034581L (no) Fremgangsmåte for autolog transplantasjon
KR20020054573A (ko) 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
EA200200414A1 (ru) Композиция антагониста вазопрессина и способ ее получения
JPH02196718A (ja) 外用液剤